188 related articles for article (PubMed ID: 26718211)
1. Stimulation of the hypoxia pathway modulates chemotherapy resistance in Hodgkin's lymphoma cells.
Kewitz S; Kurch L; Volkmer I; Staege MS
Tumour Biol; 2016 Jun; 37(6):8229-37. PubMed ID: 26718211
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.
Staege MS; Banning-Eichenseer U; Weissflog G; Volkmer I; Burdach S; Richter G; Mauz-Körholz C; Föll J; Körholz D
Exp Hematol; 2008 Jul; 36(7):886-96. PubMed ID: 18400362
[TBL] [Abstract][Full Text] [Related]
3. Glutathione-S-transferases and Chemotherapy Resistance of Hodgkin's Lymphoma Cell Lines.
Bernig T; Ritz S; Brodt G; Volkmer I; Staege MS
Anticancer Res; 2016 Aug; 36(8):3905-15. PubMed ID: 27466493
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Kewitz S; Bernig T; Staege MS
Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of Hodgkin's lymphoma cell lines to the cell cycle inhibitor roscovitine.
Foell JL; Max D; Giersberg C; Korholz D; Staege MS
Anticancer Res; 2008; 28(2A):887-94. PubMed ID: 18507033
[TBL] [Abstract][Full Text] [Related]
6. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.
Kewitz S; Staege MS
PLoS One; 2013; 8(2):e55897. PubMed ID: 23409080
[TBL] [Abstract][Full Text] [Related]
7. Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells.
Kewitz S; Staege MS
Front Oncol; 2013; 3():179. PubMed ID: 23847767
[TBL] [Abstract][Full Text] [Related]
8. The hypoxia-mimetic agent CoCl₂ induces chemotherapy resistance in LOVO colorectal cancer cells.
Yang G; Xu S; Peng L; Li H; Zhao Y; Hu Y
Mol Med Rep; 2016 Mar; 13(3):2583-9. PubMed ID: 26846577
[TBL] [Abstract][Full Text] [Related]
9. Melittin Increases Cisplatin Sensitivity and Kills KM-H2 and L-428 Hodgkin Lymphoma Cells.
Kreinest T; Volkmer I; Staege MS
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396195
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
11. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
[TBL] [Abstract][Full Text] [Related]
12. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
[TBL] [Abstract][Full Text] [Related]
13. Identification of crucial genes and prediction of small molecules for multidrug resistance of Hodgkin's lymphomas.
Huang Y; Huang Y; Zhang L; Chang A; Zhao P; Chai X; Wang J
Cancer Biomark; 2018; 23(4):495-503. PubMed ID: 30347596
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
15. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
16. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
[TBL] [Abstract][Full Text] [Related]
17. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia].
Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for Hodgkin's lymphoma.
Böll B; Borchmann P; Diehl V
Expert Opin Emerg Drugs; 2010 Dec; 15(4):585-95. PubMed ID: 20629601
[TBL] [Abstract][Full Text] [Related]
19. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
20. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
